Our previous study showed that short-term intensive insulin therapies (SIIT) can improve insulin resistance by eliminating glucolipotoxicity and induce remission in newly diagnosed T2DM patients. It's interesting that smokers seem to recover worse than non-smokers. The purpose of this study is to clarify the effect of smoking on T2DM remission from SIIT. 103 male patients (aged 47±10 ys, HbA1C 11.2±2.1%, 59 smokers) after 2-week SIIT therapy were studied. At the 1-year follow-up, the remission rate was much lower in the smokers than non-smokers (36/59 vs. 35/44). Though their insulin secretion and HbA1C were similar at the end of therapy, the smokers have statistically higher TG and worse HOMA-IR. These results indicated that smoking might affect the remission rate mainly by the weaker improved metabolism of lipids.

graphic
View largeDownload slide
graphic
View largeDownload slide
Disclosure

X. Wan: None. Z. Huang: None. L. Liu: None. Y. Li: None.

© 2019 by the American Diabetes Association.
2019
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. More information is available at http://www.diabetesjournals.org/content/license.